Poster Session 2: Allogeneic Transplants
Poster Abstracts
Longhorn Hall E (Exhibit Level 1) (Gaylord Texan)
Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using FluBu4/TLI
Sameem Abedin, MD, University of Michigan Health System;
Edward Peres, Henry Ford Hospital;
John Levine, MD, MS, University of Michigan;
Gregory Yanik, MD, University of Michigan;
Attaphol Pawarode, MD, University of Michigan;
Sung Won Choi, M.D., University of Michigan;
Daniel R. Couriel, MD, University of Michigan
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndrome (MDS): A Single Center Experience
Virginina Abello, MD, Clinica de Marly;
Licet Villamizar, MsC, Clinica de Marly;
Enrique Pedraza, MD, Clinica Marly;
Carmen Rosales, MD, Clínica de Marly;
Manuel Rosales, MD, Clínica de Marly;
Javier Figueroa, MD, Clínica de Marly;
Iris Cordoba, MD, Clínica de Marly;
Herman Esguerra, MD, Clinica De Marly
Allogeneic Match Unrelated DONOR Trasplantation: First Experience in Colombia
Virginina Abello, MD, Clinica de Marly;
Licet Villamizar, MsC, Clinica de Marly;
Enrique Pedraza, MD, Clinica Marly;
Herman Esguerra, MD, Clinica De Marly;
Carmen Rosales, MD, Clínica de Marly;
Manuel Rosales, MD, Clínica de Marly;
Javier Figueroa, MD, Clínica de Marly;
Iris Cordoba, MD, Clínica de Marly
No-Myeloablative Conditioning Regimen Cyclosphophamide-Fludarabine-ATG (Cy-Flu-ATG) Results in Better Overall Survival Compared with Myeloablative Doses of Cy with or without ATG, in High-Risk Bone Marrow Failure Syndromes (BMFS) Patients
Virginina Abello, MD, Clinica de Marly;
Licet Villamizar, MsC, Clinica de Marly;
Enrique Pedraza, MD, Clinica Marly;
Herman Esguerra, MD, Clinica De Marly;
Carmen Rosales, MD, Clínica de Marly;
Manuel Rosales, MD, Clínica de Marly;
Javier Figueroa, MD, Clínica de Marly;
Iris Cordoba, MD, Clínica de Marly;
Adriana Linares, Clinica Marly
The Addition of Extracorporeal Photophoresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft-Versus Host Disease (aGvHD, cGvHD) in Patients Undergoing a Myeloablative (MA) Hematopoietic Cell Transplant (HCT)
Sunil Abhyankar, MD, University of Kansas Medical Center;
Thomas Yankee, PhD, University of Kansas Medical Center;
Devdutta Warhadpande, University of Kansas Medical School;
Anne Hirner, RN, University of Kansas Hospital;
Jennifer Bunch, University of Kansas Medical Center;
Dean Merkel, University of Kansas Hospital;
Siddhartha Ganguly, MD, FACP, University of Kansas Medical Center;
Omar Aljitawi, University of Kansas Medical Center;
Joseph P McGuirk, DO, University of Kansas Med Ctr MS 5003
Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia
Kehinde Adekola, MD, The University of Texas MD Anderson Cancer Center;
Antonio di Stasi, MD, The University of Texas MD Anderson Cancer Center;
Roberto Ferro, The University of Texas MD Anderson Cancer Center;
Sairah Ahmed, The University of Texas MD Anderson Cancer Center;
Marcos J. G. de Lima, MD, University Hospitals Case Medical Center;
Betul Oran, MD, The University of Texas MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, The University of Texas MD Anderson Cancer Center;
Alfonso Quintas-Cardama, MD, The University of Texas MD Anderson Cancer Center;
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center;
Hagop Kantarjian, MD, The University of Texas MD Anderson Cancer Center;
Jorge Cortes, MD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Stefan O. Ciurea, MD, The University of Texas MD Anderson Cancer Center
Safety of Stem Cell Mobilization in Donors with Sickle Cell Trait
Murtadha Al-Khabori, MD, MSc, FRCPC, Sultan Qaboos University Hospital;
Fahad Al-Ghafri, Sultan Qaboos University Hospital;
Salam Al-Kindi, Sultan Qaboos University Hospital;
Arwa Z Al-Riyami, Sultan Qaboos University Hospital;
Khalil Al-Farsi, Sultan Qaboos University Hospital;
Mohammed Al-Huneini, Sultan Qaboos University Hospital;
David Dennison, Sultan Qaboos University Hospital;
Abdulhakim Al-Rawas, Sultan Qaboos University Hospital;
Shahina Daar, Sultan Qaboos University Hospital
An Assessment of the Outcomes of Second Donation Requests through the Canadian Blood Services Onematch Unrelated Registry
Iain Patrick Arseneau, Dalhousie University;
Stephen Couban, MD, FRCPC, QEII Health Sciences Centre;
Monelle Ross, Canadian Blood Services;
Kara Thompson, Capital District Health Authority;
Meagan Green, Canadian Blood Services;
Beth Amer, Canadian Blood Services;
Chris Theriault, Capital District Health Authority;
Mindy Goldman, Canadian Blood Services;
Sudeep Shivakumar, MD, Capital District Health Authority
Non-Myeloablative (NMA) Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation (Bu/Flu/TBI) Conditioining: Results of a Phase II Trial
Jonathan E Brammer, MD, Oregon Health & Science University;
Alex Stentz, MPH, Oregon Health & Science University;
James Dibb, Oregon Health & Science University;
Rachel Frires, BA, Oregon Health & Science University;
Gabrielle Meyers, MD, Oregon Health & Science University;
Peter Curtin, MD, University of California, San Diego;
Tibor Kovacsovics, MD, University of Utah Huntsman Cancer Institute;
Jose Leis, MD, PhD, Mayo Clinic Arizona;
Gundula R Palmbach, Oregon Health and Sciences University;
James Gajewski, MD, FACP, Oregon Health & Science University;
Richard T. Maziarz, MD, Oregon Health and Science University
Impact of Invasive Fungal Infections on Mortality, Length of Hospital Stay, and Costs in Allogeneic Hematopoietic Stem Cell Transplant Patients
Jenny Cai, MD, PHD, Pfizer Inc.;
Angela Prehn, PhD, Walden University;
Haran Schlamm, MD, HTS Pharma Consulting, LLC;
Massimiliano Mucci, MD, Pfizer Inc.;
Aimee Ferraro, PhD, Walden University
The Impact of ABO Incompatibility in Allogeneic Stem Cell Transplant (ALLOSCT): A Retrospective Single Center's Analysis
Jan Cerny, MD, PhD, University of Massachusetts;
Muthalagu Ramanathan, MD, UMASS Memorial University Campus;
Glen Raffel, MD, PhD, UMass Medical Center;
Natasha Fortier, PAC, UMass Memorial Medical Center;
Lindsey Shanahan, PAC, UMass Memorial Medical Center;
Tzafra Martin, PAC, UMass Memorial Medical Center;
Laura Petrillo-Deluca, PAC, UMass Memorial Medical Center;
Jayde Bednarik, PharmD, UMass Memorial Medical Center;
Rajneesh Nath, MD, UMass Memorial Medical Center
Myeloablative Conditioning Using IV Busulphan with Post Transplant Cyclophosphamide Is Feasible
Mammen Chandy, MD, Tata Medical Center;
Anupam Chakrapani, MD DM, TMC;
Sumit Goyal, MD, DM, Tata medical Center;
Reena Nair, MD, Tata Medical Center;
Vivek S Radhakrishnan, MD DM, Apollo Hospital;
Mita Roy Chowdhury, Tata medical Center
Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL
Yi-Bin Chen, MD, Massachusetts General Hospital;
Shuli Li, Dana-Farber Cancer Institute;
Candice Del Rio, RN, Massachusetts General Hospital;
Erin Coughlin, Massachusetts General Hospital;
Karen K. Ballen, MD, Massachusetts General Hospital;
Corey S. Cutler, MD, Dana-Farber Cancer Institute;
Bimalangshu R Dey, MD, PhD, Massachusetts General Hospital;
Vincent T. Ho, MD, Dana Farber Cancer Institute;
Steven L. McAfee, MD, Massachusetts General Hospital;
Thomas R. Spitzer, MD, Massachusetts General Hospital;
Edwin P. Alyea III, MD, Dana-Farber Cancer Institute
The Impact of Mold Infections after Allogeneic Transplantation
Tracey L. Churay, University of Michigan;
Holly A. Justman, University of Michigan;
Nancy L. Skurka, University of Michigan;
Gregory Yanik, MD, University of Michigan;
Steven C. Goldstein, MD, University of Michigan;
Attaphol Pawarode, MD, University of Michigan;
John Magenau, M.D., University of Michigan;
Daniel R. Couriel, MD, University of Michigan
The Clinical Significance of Human Herpes Virus 6 (HHV-6) Dnaemia in 68 Hematopoietic Cell Transplant Recipients (HSCT)
Roy F Chemaly, MD, MPH, FIDSA, FACP, The University of Texas MD Anderson Cancer Center;
Aline El Zakhem, MD, The University of Texas MD Anderson Cancer Center;
Dimpy P Shah, MD, MSPH, The University of Texas MD Anderson Cancer Center;
Nobuyoshi Mori, MD, The University of Texas MD Anderson Cancer Center;
Lior Nesher, MD, The University of Texas MD Anderson Cancer Center;
Ella Ariza-Heredia, MD, The University of Texas MD Anderson Cancer Center;
Victor E Mulanovich, MD, The University of Texas MD Anderson Cancer Center;
Partow Kebriaei, MD, UT M.D. Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Gabriela Rondon, MD, UT M.D. Anderson Cancer Center
Frequency and Impact of Allogeneic Hematopoetic Stem Cell Transplant and Preparative Regimen in Patients with High and Intermediate Risk AML at a Small Center
Shatha Farhan, Henry Ford Hospital;
Klodiana Neme, PharmD, Henry Ford Hospital;
Nancy Mikulandric, PharmD, Henry Ford Hospital;
Kenneth Ruemenapp, Henry Ford Hospital;
Mary Ann Trapp, Henry Ford Hospital;
Sarah Szymanski, Henry Ford hospital;
Edward Peres, Henry Ford Hospital;
Nalini Janakiraman, MD, Henry Ford Health Systems
Impact of Dysplasia on Outcome of Patients with Acute Myeloid Leukemia and Response to Allogeneic Hematopoetic Stem Cell Transplant
Shatha Farhan, Henry Ford Hospital;
Klodiana Neme, PharmD, Henry Ford Hospital;
Nancy Mikulandric, PharmD, Henry Ford Hospital;
Kenneth Ruemenapp, Henry Ford Hospital;
Sarah Szymanski, Henry Ford hospital;
Mary Ann Trapp, Henry Ford Hospital;
Edward Peres, Henry Ford Hospital;
Nalini Janakiraman, MD, Henry Ford Health Systems
Phenytoin Versus Levetiracetam for Busulfan-Induced Seizure Prophylaxis and Hematopoietic Stem Cell Transplantation Outcomes
Shatha Farhan, Henry Ford Hospital;
Klodiana Neme, PharmD, Henry Ford Hospital;
Nancy Mikulandric, PharmD, Henry Ford Hospital;
Danielle Pelland, Henry Ford Hospital;
Susan Wautelet, Henry Ford Hospital;
Sarah Szymanski, Henry Ford hospital;
Kenneth Ruemenapp, Henry Ford Hospital;
Mary Ann Trapp, Henry Ford Hospital;
Edward Peres, Henry Ford Hospital;
Nalini Janakiraman, MD, Henry Ford Health Systems
Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients up to Age Seventy-Five with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Teresa Field, MD PhD, H. Lee Moffitt Cancer Center;
Janelle Perkins, PharmD, Moffitt Cancer Center;
Ryan Hillgruber, H. Lee Moffitt Cancer Center and Research Institute;
Taiga Nishihori, MD, H. Lee Moffitt Cancer Center and Research Institute;
Marcie Riches, MD, MS, H. Lee Moffitt Cancer Center;
Asmita Mishra, MD, H. Lee Moffitt Cancer Center;
Joseph Pidala, MD, MS, H. Lee Moffitt Cancer Center and Research Institute;
Frederick Locke, H. Lee Moffitt Cancer Center;
Lia Elena Perez, M.D., H. Lee Moffitt Cancer Center;
Brian Betts, MD, H. Lee Moffitt Cancer Institute;
Ernesto Ayala, H. Lee Moffitt Cancer Center;
Melissa Alsina, MD, H. Lee Moffitt Cancer Center and Research Institute;
Jose-Leonel Ochoa, MD, H. Lee Moffitt Cancer Center;
Eric Padron, MD, H. Lee Moffitt Cancer Center;
Jeffery Lancet, MD, H. Lee Moffitt Cancer Center;
Hugo Fernandez, MD, H. Lee Moffitt Cancer Center;
Alan F. List, MD, H. Lee Moffitt Cancer Center & Research Institute;
Rami Komrokji, H. Lee Moffitt Cancer Center;
Mohamed Kharfan-Dabaja, H. Lee Moffitt Cancer Center;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center and Research Institute
Impact of Granulocyte Transfusion in Patients Submitted Allogeneic Hematopoietic Progenitor Cell Transplantation – a Single Center Experience in Brazil
Vaneuza Araujo Moreira Funke, MD, MS, Federal University of Parana;
Andresa Melo, MD, Federal University of Parana;
Diogo Kloppel, MD, Federal University of Parana;
Marco Bitencourt, MD, Federal University of Parana;
Samir Nabhan, MD, Federal University of Parana;
Daniela C. Setubal, MD, Federal University of Parana;
Caroline Sola, Hospital De Clinicas Da Ufpr;
Michel Michels Oliveira, MD, Federal University of Parana;
Joao Farias, Federal University of Parana;
Giorgio Baldanzi, Federal University of Parana;
Clovis Arns Cunha, Federal University of Parana;
Carmem Bonfim, MD, Federal University of Parana;
Ricardo Pasquini, MD, Federal University of Parana;
Mariester Malvezzi, MD. MS, Federal University of Parana
Lower Incidence of CMV Reactivation Following Allogeneic Stem Cell Transplantation Despite a High Seroprevalence - a Single Centre Experience
Biju George, MD, Christian Medical College;
Anup Devasia, MD, Christian Medical College;
Vikram Mathews, MD, Christian Medical College;
Kavitha Lakshmi, MSc, Christian Medical College;
Auro Viswabandya, MD, Christian Medical College;
Aby Abraham, MD, Christian Medical College;
Abhijeet Ganapule, MD, Christian Medical College;
Alok Srivastava, MD, Christian Medical College
Myelodysplastic Syndrome Patients with Disease Progression after Cytoreductive Therapy Have Poor Survival and High Non-Relapse Mortality after Full-Intensity Allogeneic Hematopoietic Cell Transplantation
Aaron T. Gerds, MD, MS, Cleveland Clinic Taussig Cancer Institute;
Lisa Rybicki, MS, Cleveland Clinic Taussig Cancer Institute;
Betty Ky Hamilton, MD, Cleveland Clinic Taussig Cancer Institute;
Ronald Sobecks, MD, Cleveland Clinic Taussig Cancer Institute;
Hien Duong, MD, Cleveland Clinic Taussig Cancer Institute;
Steven Andresen, DO, Cleveland Clinic Taussig Cancer Institute;
Rabi Hanna, MD, Cleveland Clinic Taussig Cancer Institute;
Elaina Corbett, BSN, RN, Cleveland Clinic Taussig Cancer Institute;
Jamie Starn, BSN RN, Cleveland Clinic Taussig Cancer Institute;
Brian Bolwell, MD, Cleveland Clinic Taussig Cancer Institute;
Navneet S. Majhail, MD, MS, Cleveland Clinic Foundation;
Matt E. Kalaycio, MD, Cleveland Clinic Taussig Cancer Institute
Characteristics and Outcome of Cytomegalovirus (CMV) Infections in 95 Cord Blood Transplant (CBT) Recipients: The MD Anderson Experience
Shashank S Ghantoji, MD, MPH, The University of Texas MD Anderson Cancer Center;
Sumana Goddu, MD, MPH, University of Texas School of Public Health;
Swapna Sreenivasula, MD, MPH, University of Texas School of Public Health;
Dimpy P Shah, MD, MSPH, The University of Texas MD Anderson Cancer Center;
Betul Oran, MD, The University of Texas MD Anderson Cancer Center;
Katy Rezvani, MD, The University of Texas MD Anderson Cancer Center;
Gabriela Rondon, MD, UT M.D. Anderson Cancer Center;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
Roy F Chemaly, MD, MPH, FIDSA, FACP, The University of Texas MD Anderson Cancer Center
Fludarabine Metabolite Level on Day Zero Does Not Affect Outcomes of Hematopoietic Cell Transplantation in Patients with Normal Renal Function
Cameron D. Griffiths, MD, Alberta Health Services;
Ella S.M Ng, MSc, Alberta Health Services;
Bill Kangarloo, MSc., Alberta Health Services;
Tyler S. Williamson, PhD, Queen's University;
Reanne Booker, Tom Baker Cancer Centre;
Ping Yue, MD, Tom Baker Cancer Center;
Peter Raymond Duggan, MD, Tom Baker Cancer Centre/Foothills Hospital;
Mary Lynn Savoie, MD, FRCPC, Tom Baker Cancer Centre/Foothills Hospital;
Chris Brown, MD, Tom Baker Cancer Centre/Foothills Hospital;
Andrew Daly, Tom Baker Cancer Centre/Foothills Hospital;
James A Russell, MA, MB, Tom Baker Cancer Centre/Foothills Hospital;
Jan Storek, MD, PhD, Tom Baker Cancer Centre/Foothills Hospital
Elevated Expression of Interferon-Induced Genes and Damage Associated Molecular Pattern Receptor Genes in Chronic Graft Versus Host Disease
Fran Hakim, PhD, NCI;
Ping Jin, MD, Clinical Center, NIH;
Sarfraz Memon, MD, National Cancer Institute, NIH;
Xiao-Yi Yan, MD, National Cancer Institute, NIH;
Matin Imanguli, MD, DDS, National Cancer Institute, NIH;
Kristin Baird, MD, National Cancer Institute, NIH;
Edward W Cowen, MD, National Cancer Institute, NIH;
David F. Stroncek, MD, Clinical Center, NIH;
Ronald Gress, MD, NCI;
Steven Z. Pavletic, MD, National Cancer Institute
Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Betty Ky Hamilton, MD, Cleveland Clinic Taussig Cancer Institute;
Lisa Rybicki, MS, Cleveland Clinic Taussig Cancer Institute;
Aaron Gerds, MD, MS, Cleveland Clinic Taussig Cancer Institute;
Rabi Hanna, MD, Cleveland Clinic Taussig Cancer Institute;
Ronald Sobecks, MD, Cleveland Clinic Taussig Cancer Institute;
Hien Duong, MD, Cleveland Clinic Taussig Cancer Institute;
Jamie Starn, BSN RN, Cleveland Clinic Taussig Cancer Institute;
Elaina Corbett, BSN, RN, Cleveland Clinic Taussig Cancer Institute;
Brian Bolwell, MD, Cleveland Clinic Taussig Cancer Institute;
Navneet S. Majhail, MD, MS, Cleveland Clinic Foundation;
Matt E. Kalaycio, MD, Cleveland Clinic Taussig Cancer Institute
Voriconazole Exposure and the Risk of Cutaneous Squamous Cell Carcinoma in Allogeneic Hematopoietic Stem Cell Transplant Patients
Shahrukh Hashmi, MD, Mayo Clinic;
Daniel Wojenski, Pharm.D RPh, Mayo Clinic;
Julianna Merten, PharmD, Mayo Clinic Rochester;
Robert Wolf, PharmD, Mayo Clinic;
Gabriel Bartoo, PharmD, Mayo Clinic;
John Wilson, MD, Mayo Clinic;
Rokea El-azhary, MD PhD, Mayo Clinic;
Ross Dierkhising, MS, Mayo Clinic;
Mrinal Patnaik, MD, Mayo Clinic;
William Hogan, MBBCh, Mayo Clinic;
Mark R Litzow, MD, Mayo Clinic
Hepatitis Due to Human Herpesvirus 6 after Hematopoietic Stem Cell Transplantation
Joshua A Hill, MD, Fred Hutchinson Cancer Research Center;
David Myerson, MD, PhD, University of Washington Medical Center;
Ruth Hall Sedlak, PhD, University of Washington;
Keith R Jerome, MD, PhD, University of Washington;
Danielle Zerr, MD, MPH, University of Washington Medical Center
Prevalence of Chromosomally Integrated Human Herpesvirus 6 (HHV-6) Among Patients with HHV-6-Associated Post-Stem Cell Transplant Acute Limbic Encephalitis
Joshua A Hill, MD, Fred Hutchinson Cancer Research Center;
Danielle Zerr, MD, MPH, Fred Hutchinson Cancer Research Center;
Ruth Hall Sedlak, PhD, University of Washington;
Keith R Jerome, MD, PhD, University of Washington;
Michael J. Boeckh, MD, PhD, University of Washington
Comparison of Fludarabine and Total Body Irradiation (FluTBI) to Fludarabine without TBI (Flu) Based Nonmyeloabltive Conditioning (NMA) Prior to Hematopoietic Cell Transplantation (HCT) for Lymphoma
Sanghee Hong, Medical College of Wisconsin;
Jennifer Le Rademacher, PhD, Medical College of Wisconsin;
Jeanette Carreras, MPH, Medical College of Wisconsin;
Tara M. Kroll, MD, Medical College of Wisconsin;
John P. Klein, PhD, Medical College of Wisconsin;
Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin
Pretransplant Immunosuppression Followed By Reduced Toxicity Conditioning and Stem Cell Transplantation in High Risk Thalassemia
Suradej Hongeng, MD, Faculty of Medicine Ramathibodi Hospital, Mahidol University;
Samart Pakakasama, MD, Ramathibodi hospital;
Usanarat Anurathapan, MD, Ramathibodi hospital;
Borje S. Andersson, MD, PhD, M. D. Anderson Cancer Center
Outcome Of Hematopoietic Stem Cell Transplantation For Wiskott-Aldrich Syndrome
Sakara Hutspardol, MD, Hospital for Sick Children;
Adam Gassas, MD, MBChB, MSc, MRCP, DCH, The Hospital for Sick Children;
John Doyle, MD FRCPC FAAP, CancerCare Manitoba;
Muhammad Ali, MD, The Hospital for Sick Children;
R. Maarten Egeler, MD, PhD, Hospital for Sick Children;
Eyal Grunebaum, MD, Hospital for Sick Children;
Tal Schechter-Finkelstein, MD, Hospital for Sick Children
A Novel Reduced Intensity Conditioning Regimen for Patients with High Risk Hematologic Malignancies Undergoing Conventional Allogeneic Stem Cell Transplantation
Gabriela Hobbs, MD, Memorial Sloan-Kettering Cancer Center;
Navjeet Kaur, MD, Presbyterian Hospital;
Doris M. Ponce, MD, Memorial Sloan-Kettering Cancer Center;
Patrick Hilden, PhD, Memorial Sloan-Kettering Cancer Center;
Hugo Castro-Malaspina, M.D., Memorial Sloan-Kettering Cancer Center;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Jenna D. Goldberg, MD, Memorial Sloan-Kettering Cancer Center;
Esperanza Papadopoulos, MD, Memorial Sloan-Kettering Cancer Center;
Ann A. Jakubowski, PhD MD, Memorial Sloan-Kettering Cancer Center;
Craig Steven Sauter, MD, Memorial Sloan Kettering Cancer Center;
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Juliet N. Barker, MBBS, FRACP, Memorial Sloan-Kettering Cancer Center;
Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center
Fludarabine, Intravenous Busulfan, and Total Body Irradiation (FluBuTBI) Conditioning for Allogeneic Peripheral Blood Stem Cell Transplantation the Western Pennsylvania Cancer Institute Experience
Aron Kefela, MD, Allegheny Health Network;
Entezam Sahovic, MD, Allegheny Health Network;
Jocelyn De Yao, MD, Allegheny Health Network;
Santhosh Sadashiv, MD, Allegheny Health Network;
James Rossetti, DO, Allegheny Health Network;
Salman Fazal, MD, Allegheny Health Network;
Cyrus Khan, MD, Allegheny Health Network;
Gina Berteotti, Western Pennsylvania Cancer Institute;
John Lister, M.D., Western Pennsylvania Cancer Institute
Comparison of Peripheral Blood Vs. Bone Marrow Chimerism after a Reduced Intensity Conditioning Allogeneic Stem Cell Transplant
Gina Marie Keiffer, MD, Kimmel Cancer Center, Thomas Jefferson University;
Sameh Gaballa, MD, Kimmel Cancer Center, Thomas Jefferson University;
Neil D. Palmisiano, MD, Kimmel Cancer Center, Thomas Jefferson University;
Gunjan L. Shah, MD MS, Tufts Medical Center;
Rachael Grosso, MS-III, Thomas Jefferson University Hospital;
Shannon Rudolph, MS, Kimmel Cancer Center, Thomas Jefferson University;
Sarah Rosado, Kimmel Cancer Center, Thomas Jefferson University;
Matthew Carabasi, MD, Kimmel Cancer Center, Thomas Jefferson University;
Onder Alpdogan, MD, Kimmel Cancer Center, Thomas Jefferson University;
John L. Wagner, MD, Kimmel Cancer Center, Thomas Jefferson University;
Margaret Kasner, MD, Kimmel Cancer Center, Thomas Jefferson University;
Ubaldo Martinez, MD, Kimmel Cancer Center, Thomas Jefferson University;
Mark Weiss, MD, Kimmel Cancer Center, Thomas Jefferson University;
Dolores Grosso, DNP, Kimmel Cancer Center, Thomas Jefferson University;
Neal Flomenberg, MD, Kimmel Cancer Center, Thomas Jefferson University;
Joanne Filicko, MD, Kimmel Cancer Center, Thomas Jefferson University
Addition Of Thiotepa To The Conditioning Regimen Significantly Improves Transplant Outcomes In Children Undergoing Cord Blood Transplantation For Non-Malignant Disease. Lurie Children's Hospital Of Chicago's Experience
Mehboob Merchant, MBBS, SLS (ASCP), Northwestern Memorial Hospital;
Reggie E Duerst, MD, Ann & Robert H. Lurie Children's Hospital of Chicago;
Alfred Rademaker, Ph.D, Northwestern University Feinberg School of Medicine;
Morris Kletzel, MD, FAAP, MBA, Northwestern University Feinberg School of Medicine
Increased Transplant Related Mortality and Poor Donor Cell Chimerism in African American Children Undergoing Umbilical Cord Blood Transplantation. Institutional Experience at Lurie Children's Hospital of Chicago
Mehboob Merchant, MBBS, SLS (ASCP), Northwestern Memorial Hospital;
Reggie E Duerst, MD, Ann & Robert H. Lurie Children's Hospital of Chicago;
Alfred Rademaker, Ph.D, Northwestern University Feinberg School of Medicine;
Morris Kletzel, MD, FAAP, MBA, Northwestern University Feinberg School of Medicine
Allogeneic Transplantation for MDS/AML Patients with Germline GATA2 Mutations
Samith Kochuparambil, MD, Mayo Clinic;
Amie Jackson, MD, Mayo Clinic;
Mark R Litzow, MD, Mayo Clinic;
Shakila P Khan, MD, Mayo Clinic;
Vilmarie Rodriguez, MD, Mayo Clinic;
Roshini Abraham, Phd, Mayo Clinic;
William Hogan, MBBCh, Mayo Clinic;
Mrinal Patnaik, MD, Mayo Clinic
Post-Transplant Isoagglutinin Induced Pure Red Cell Aplasia; Incidence and Clinic Outcomes
Samith Kochuparambil, MD, Mayo Clinic;
Mark R Litzow, MD, Mayo Clinic;
William Hogan, MBBCh, Mayo Clinic;
Shahrukh Hashmi, MD, Mayo Clinic;
Dennis Gastineau, MD, Mayo Clinic;
Mrinal Patnaik, MD, Mayo Clinic
Prolonged Survival Can be Achieved By Primary Plasma Cell Leukemia and Multiply-Refractory Multiple Myeloma Patients with Responding Disease Prior to Melphalan/Total Body Irradiation-Conditioned Myeloablative Allogeneic Hematopoietic Cell Transplantation
Daniel J. Landsburg, MD, University of Pennsylvania;
Dan T. Vogl, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
John P. Plastaras, MD, University of Pennsylvania;
Jacqueline Smith, CRNP, University of Pennsylvania;
Patricia Mangan, CRNP, University of Pennsylvania;
Brenda Shelly, CRNP, University of Pennsylvania;
Brendan M. Weiss, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Adam D. Cohen, MD, University of Pennsylvania;
David L. Porter, MD, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Edward A. Stadtmauer, MD, University of Pennsylvania, Perelman School of Medicine
Outcomes of Relapse of AML Post Allogeneic Transplantation in the Era of Hypomethylating Agents: An Analysis of 162 Allogeneic Transplants from a Single Center
Justin LaPorte, PharmD, The Blood and Marrow Transplant Program at Northside Hospital;
Xu Zhang, PhD, Ga State University Mathematics;
Zaamin Hussain, The Blood and Marrow Transplant Program at Northside Hospital;
Stacey Brown, BA, CCRP, The Blood and Marrow Transplant Program at Northside Hospital;
Connie Sizemore, PharmD, The Blood and Marrow Transplant Program at Northside Hospital;
Melissa Sanacore, PharmD, The Blood and Marrow Transplant Program at Northside Hospital;
Ron Mihelic, PhramD, The Blood and Marrow Transplant Program at Northside Hospital;
Mindy Leech, PharmD, The Blood and Marrow Transplant Program at Northside Hospital;
Lawrence Morris, MD, The Blood and Marrow Transplant Program at Northside Hospital;
H. Kent Holland, MD, The Blood and Marrow Transplant Program at Northside Hospital;
Scott R. Solomon, MD, The Blood and Marrow Transplant Program at Northside Hospital;
Asad Bashey, MD PhD, The Blood and Marrow Transplant Program at Northside Hospital
Variable Success Rates of Haplo-Cord Transplants in High Risk Patients: A Minimum Serotherapy Exposure Is a Prerequisite for Sustainable Engrafting
Caroline Lindemans, MD, PhD, University Medical Center Utrecht;
Liane te Boome, MD, UMC Utrecht;
CM Jol- van der Zijde, BSc, Leiden University Medical Center;
AM Wensing, MD, PhD, University Medical Center Utrecht;
R. Admiraal, MD, Leiden University Medical Center;
Marc Bierings, MD, PhD, University Medical Center Utrecht;
Jurgen Kuball, MD, PhD, University Medical Center Utrecht;
Jaap-Jan Boelens, MD, PhD, University Medical Center Utrecht
Clinical Profile and Outcome of Patients with Graft Rejection Following Related HLA Matched Allogeneic Stem Cell Transplant for β Thalassemia Major
Vikram Mathews, MD, Christian Medical College;
Abhijeet Ganapule, MD, Christian Medical College;
Biju George, MD, Christian Medical College;
Kavitha Lakshmi, MSc, Christian Medical College;
Aby Abraham, MD, Christian Medical College;
Auro Viswabandya, MD, Christian Medical College;
Alok Srivastava, MD, Christian Medical College
Factors Influencing Tolerance to Total Body Irradiation (400 cGy) for Hematopoietic Stem Cell Transplantation
Prerna Mewawalla, M.D., Western Pennsylvania Cancer Institute;
Patrizia Guerrieri, M.D., Western Pennsylvania Hospital;
Prashant Jani, M.D., Western Pennsylvania Hospital;
Gina Berteotti, Western Pennsylvania Cancer Institute;
Entezam A Sahovic, M.D., Western Pennsylvania Cancer Institute;
John Lister, M.D., Western Pennsylvania Cancer Institute
Use of Leflunomide in the Treatment of Recalcitrant CMV Infection in Immunocompromised Patients
Nobuyoshi Mori, MD, The University of Texas MD Anderson Cancer Center;
Jakapat Vanichanan, MD, The University of Texas MD Anderson Cancer Center;
Dimpy P Shah, MD, MSPH, The University of Texas MD Anderson Cancer Center;
Frank Tverdek, Pharm D, The University of Texas MD Anderson Cancer Center;
Jean Tayar, MD, The University of Texas MD Anderson Cancer Center;
Ella Ariza-Heredia, MD, The University of Texas MD Anderson Cancer Center;
Victor E Mulanovich, MD, The University of Texas MD Anderson Cancer Center;
Roy F Chemaly, MD, MPH, FIDSA, FACP, The University of Texas MD Anderson Cancer Center
Allogenic (Allo) Stem Cell Transplant (SCT) in Patients over Age 70 Years: A Single Center's Experience
Zeina Al-Mansour, MD, University of Massachusetts;
Jan Cerny, MD, PhD, University of Massachusetts;
Muthalagu Ramanathan, MD, UMASS Memorial University Campus;
Glen Raffel, MD, PhD, UMass Medical Center;
Mridula George, MD, UMass Medical Center;
Laura Petrillo-Deluca, PAC, UMass Memorial Medical Center;
Lindsey Shanahan, PAC, UMass Memorial Medical Center;
Jayde Bednarik, PharmD, UMass Memorial Medical Center;
Zankar Desai, University of Massachusetts Medical Center;
Aimee Kroll-Desrosiers, MS, University of Massachussets;
Rajneesh Nath, MD, UMass Memorial Medical Center
Hematopoietic Stem Cell Transplantation (HSCT) for Dyskeratosis Congenita(DC): A Review of 12 Patients(pts) Transplanted in Curitiba, Brazil
Samantha Nichele, MD, Federal University of Parana;
Lisandro Ribeiro, MD, Federal University of Parana;
Gisele Loth, MD, Federal University of Parana;
Cilmara Kuwahara, MD, Universidade Federal do Paraná;
Carlos Eduardo Sá Araújo, MD, Federal University of Parana;
Ana Luiza Melo Rodrigues, MD, Federal University of Parana;
Marco Bitencourt, MD, Federal University of Parana;
Adriana Koliski, MD, Federal University of Parana;
Rodrigo Calado, MD;PhD, Universidade Paulista de Medicina;
Mariester Malvezzi, MD. MS, Federal University of Parana;
Ricardo Pasquini, MD, Federal University of Parana;
Rebeca Toassa Mousquer, MD, Federal University of Parana;
Carmem Bonfim, MD, Federal University of Parana
Recipient T-Cell Repertoire Diversity after Double Umbilical Cord Transplantation Correlates with Non-Relapse Mortality and Survival
Sarah Nikiforow, MD PhD, Dana-Farber Cancer Institute;
Haesook T Kim, PhD, Dana-Farber Cancer Institute;
Sean M McDonough, MS, Dana-Farber Cancer Institute;
Ryan Emerson, PhD, Adaptive Biotechnologies;
David Hamm, MSc, Adaptive Biotechnologies;
Karen K. Ballen, MD, Massachusetts General Hospital;
Vassiliki A. Boussiotis, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute;
Joseph H Antin, MD, Dana-Farber Cancer Institute;
Jerome Ritz, MD, Dana-Farber Cancer Institute;
Corey S. Cutler, MD, Dana-Farber Cancer Institute
Co-Stimulatory Blockade Permits Transplantation of Human Hematopoitic Stem Cells and HLA Incompatible T Cells in NOD/SCID γ Null (NSG) Mice
Annie Oh, MD, University of Illinois Hospital & Health Sciences System;
Dolores Mahmud, PhD, University of Illinois Hospital & Health Sciences System;
Benedetta Nicolini, University of Illinois Hospital & Health Sciences System;
Elisa Bonetti, University of Illinois Hospital & Health Sciences System;
Nadim Mahmud, MD, PhD, University of Illinois Hospital & Health Sciences System;
Pritesh Patel, MB, ChB, University of Illinois Hospital & Health Sciences System;
Damiano Rondelli, MD, University of Illinois Hospital & Health Sciences System
Hematopoietic Cell Transplant Co-Morbidity Index (HCT-CI): Ability to Predict Outcomes in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)
Neil D. Palmisiano, MD, Kimmel Cancer Center, Thomas Jefferson University;
Sameh Gaballa, MD, Kimmel Cancer Center, Thomas Jefferson University;
Onder Alpdogan, MD, Kimmel Cancer Center, Thomas Jefferson University;
Matthew Carabasi, MD, Kimmel Cancer Center, Thomas Jefferson University;
Joanne Filicko, MD, Kimmel Cancer Center, Thomas Jefferson University;
Margaret Kasner, MD, Kimmel Cancer Center, Thomas Jefferson University;
Ubaldo Martinez, MD, Kimmel Cancer Center, Thomas Jefferson University;
John L. Wagner, MD, Kimmel Cancer Center, Thomas Jefferson University;
Mark Weiss, MD, Kimmel Cancer Center, Thomas Jefferson University;
Neal Flomenberg, MD, Kimmel Cancer Center, Thomas Jefferson University;
Dolores Grosso, DNP, Kimmel Cancer Center, Thomas Jefferson University
Prognostic Value of Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) in Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplant
Oana Paun, MD, University of California, San Francisco;
Tamila L Kindwall-Keller, DO, MS, University of Virginia School of Medicine;
Hillard M. Lazarus, MD, University Hospitals Case Medical Center;
Mary J. Laughlin, MD, University Virginia Hospital;
Merle Kolk, University Hospitals Case Medical Center;
Richard Creger, University Hospitals;
Huda Salman, MD, University Hospitals;
Stan L. Gerson, MD, University Hospital Case Medical Center;
Brenda Cooper, MD, University Hospitals, Case Medical Center
Double Unit Umbilical Cord Blood Transplant for Adults with Acute Leukemia and Myelodysplastic Syndrome Results in Comparable Outcome As Matched Sibling or Unrelated Donor Transplant Only after Myeloablative Conditioning but Not Reduced Intensity Conditio
Michelle Limei Poon, MD, National University Hospital;
Yeh Ching Linn, MD, Singapore General Hospital;
Ziyi Lim, MD, National University Hospital;
Aloysius Ho, MD, Singapore General Hospital;
Lip Kun Tan, MD, National University Hospital;
Teck Guan Soh, Master Degree, National University Health System;
Kk Heng, Singapore General Hospital;
Belinda Tan, National University Hospital;
- Yelly, National University Hospital;
Jing Jing Lee, Singapore General Hospital;
Heng Joo Ng, MD, Singapore General Hospital;
William Y K Hwang, MD, Singapore General Hospital;
Liang Piu Koh, MD, National University Hospital
Allogeneic Hematopoietic Stem Cell Transplantation (aHSCT) In Adult Patients With Acute Lymphoblastic Leukemia (ALL): Experience Of The Hematology-Oncology Department At Pontificia Universidad Católica De Chile Between 1994 and 2013
Daniel Ernst, MD, Pontifical Catholic University;
Pablo Bertin, MD, Pontifical Catholic University;
Bruno Nervi, MD, Pontifical Catholic University;
Veronica Jara, RN, Pontifical Catholic University;
Mauricio Ocqueteau, MD, Pontifical Catholic University;
Mauricio Sarmiento, MD, Pontifical Catholic University;
Karen Escobar, MD, Pontifical Catholic University;
Pablo A Ramirez, MD, Pontifical Catholic University
Critical Care Unit Admission Of Hematopoietic Stem Cell Transplant Patients In An University Hospital In Chile
Pablo A Ramirez, MD, Pontifical Catholic University;
Karen Escobar, MD, Pontifical Catholic University;
Patricio Rojas, MD, Pontifical Catholic University;
Pablo Bertin, MD, Pontifical Catholic University;
Bruno Nervi, MD, Pontifical Catholic University;
Veronica Jara, RN, Pontifical Catholic University;
Mauricio Ocqueteau, MD, Pontifical Catholic University;
Maria Jose Garcia, MD, Pontifical Catholic University;
Mauricio Sarmiento, MD, Pontifical Catholic University;
Daniel Ernst, MD, Pontifical Catholic University;
Maria Alejandra Rodriguez, MD, Pontifical Catholic University
Prospective Validation of a Busulfan Pharmacokinetic Model in Children: Therapeutic Drug Monitoring Remains of Utmost Importance to Optimize Outcomes of HCT
Elisabeth van van Reij, PharmD, University Medical Center Utrecht;
Erik van Maarseveen, PharmD, University Medical Center Utrecht;
Imke Bartelink, PharmD, PhD, University Medical Center Utrecht;
Carin Rademaker, PharmD, PhD, University Medical Center Utrecht;
Toine Egberts, Professor, University Medical Center Utrecht;
Jaap-Jan Boelens, MD, PhD, University Medical Center Utrecht
High CD8 Cell Doses Correlate with Reduced Relapse Risk and Improved Survival after Allogeneic Peripheral Blood Stem-Cell Transplantation with Reduced-Intensity Conditioning
Ran Reshef, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Selina Luger, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Alison Loren, MD, MS, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Elizabeth O. Hexner, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Sunita D. Nasta, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Noelle V. Frey, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Edward A. Stadtmauer, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Jacqueline Smith, CRNP, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
David L. Porter, MD, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Subsequent Malignant Neoplasms After Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and Outpatient Conduction
Gabriela Zamora-Ortiz, MD, Centro de Hematologia y Medicina Interna;
Sara Velazquez-Sanchez-de-Cima, MD, Centro de Hematologia y Medicina Interna de Puebla;
Sergio Ponce-de-León, MD, Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran;
Cesar Homero Gutierrez-Aguirre, MD, University Hospital of Monterrey;
Guillermo Jose Ruiz-Delgado, MD, Clinica Ruiz;
David Gomez-Almaguer, MD, University Hospital of Monterrey;
Guillermo J. Ruiz-Arguelles, MD, FRCP(Glasg), MACP, Clinica Ruiz de Puebla
Reduced Intensity Fludarabine and Intravenous Busulfan (FB2) for Allogeneic Peripheral Blood Stem Cell Transplantation
Santhosh Sadashiv, MD, Allegheny Health Network;
Entezam Sahovic, MD, Allegheny Health Network;
Pritam Tayshetye, MD, Allegheny Health Network;
Jocelyn De Yao, MD, Allegheny Health Network;
Aron Kefela, MD, Allegheny Health Network;
James Rossetti, DO, Allegheny Health Network;
Salman Fazal, MD, Allegheny Health Network;
Cyrus Khan, MD, Allegheny Health Network;
Gina Berteotti, Western Pennsylvania Cancer Institute;
John Lister, M.D., Western Pennsylvania Cancer Institute
Utility of CMV PCR in the Evaluation of Allograft Recipients Presenting with Diarrhea
Douglas W Sborov, M.D., The Ohio State University;
Leah Marsh, B.S., The Ohio State University;
Martha Yearsley, M.D., The Ohio State University;
Susan Geyer, Ph.D., The Ohio State University;
William Falk, B.S, The Ohio State University;
Steven M. Devine, MD, Ohio State Medical Center;
Craig C Hofmeister, MD, The Ohio State University
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in Patients with End Stage Renal Disease Requiring Dialysis – a Single Institution Experience
Mazyar Shadman, MD, MPH, University of Washington;
Brenda M. Sandmaier, MD, Fred Hutchinson Cancer Research Center;
David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center;
John M. Pagel, MD, PhD, Fred Hutchinson Cancer Research Center;
Sangeeta Hingorani, MD, MPH, University of Washington
Rarity of Donor-Derived Malignancy after Allogeneic BMT with High-Dose Post-Transplantation Cyclophosphamide
Heather Jill Symons, MD, MHS, Sidney Kimmel Cancer Center, Johns Hopkins University;
Huzefa Mogri, BS, Johns Hopkins Medical Institution;
Jennifer A. Kanakry, MD, Sidney Kimmel Cancer Center, Johns hopkins University;
Richard Ambinder, MD, PhD, Johns Hopkins University School of Medicine;
Leo Luznik, MD, Johns Hopkins University School of Medicine;
Ephraim Fuchs, MD, Johns Hopkins University School of Medicine;
Richard J. Jones, MD, The Johns Hopkins University;
Yvette L. Kasamon, MD, Sidney Kimmel Cancer Center, Johns Hopkins University
Ex –Vivo T Cell Depleted Allogeneic (TCD) Hematopoietic Stem Cell Transplantation for Advanced Chronic Myelofibrosis: MSKCC Experience
Roni Tamari, Memorial Sloan-Kettering Cancer Center;
Ann A. Jakubowski, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Esperanza Papadopoulos, MD, Memorial Sloan-Kettering Cancer Center;
Craig Sauter, MD, Memorial Sloan-Kettering Cancer Center;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Hugo Castro-Malaspina, M.D., Memorial Sloan-Kettering Cancer Center
Prospective Multicenter Phase II Study of Myeloablative Conditioning Consisted of Intravenous Busulfan and Fludarabine +/- Total Body Irradiation for Older Patients (55 years and older): Final Analysis of the JSCT FB09 Study
Naoyuki Uchida, MD, Toranomon Hospital;
Michihiro Hidaka, MD, National Hospital Organization Kumamoto Medical Center;
Toru Sakura, MD, Saiseikai Maebashi Hospital;
Toshihiro Miyamoto, MD, Kyushu University Graduate School of Medical Science;
Tomoaki Fujisaki, MD, Matsuyama Red Cross Hospital;
Tetsuya Eto, MD, Hamanomachi Hospital;
Yoshinobu Maeda, MD, Okayama University;
Kenji Fukuno, MD, Gifu Red Cross Hospital;
Kana Matsumoto, PhD, Doshisha Women's College of Liberal Arts;
Kunihiko Morita, PhD, Doshisha Women's College of Liberal Arts;
Junji Kishimoto, PhD, Kyushu University Hospital;
Takahiro Fukuda, MD, National Cancer Center Hospital;
Takanori Teshima, MD, Kyushu University Graduate School of Medical Science;
Shuichi Taniguchi, MD, PhD, Toranomon Hospital;
Shin-Ichiro Mori, MD, St Luke's International Hospital;
Mine Harada, MD, Karatsu Higashimatsuura Medical Association
Characteristics and Outcomes of Influenza a Infection in Hematologic Malignancy (HM) Patients and Hematopoietic Stem Cell Transplant
Jakapat Vanichanan, MD, The University of Texas MD Anderson Cancer Center;
Dimpy P Shah, MD, MSPH, The University of Texas MD Anderson Cancer Center;
Lior Nesher, MD, The University of Texas MD Anderson Cancer Center;
Ella Ariza-Heredia, MD, The University of Texas MD Anderson Cancer Center;
Roy F Chemaly, MD, MPH, FIDSA, FACP, The University of Texas MD Anderson Cancer Center
Engraftment and Immune Recovery (IR) in Good Risk Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): Comparison of Two Different Approaches Using Cyclophosphamide (CY) for T-Cell Tolerization
John L. Wagner, MD, Kimmel Cancer Center, Thomas Jefferson University;
Dolores Grosso, DNP, Kimmel Cancer Center, Thomas Jefferson University;
Onder Alpdogan, MD, Kimmel Cancer Center, Thomas Jefferson University;
Matthew Carabasi, MD, Kimmel Cancer Center, Thomas Jefferson University;
Joanne Filicko, MD, Thomas Jefferson University Hospital;
Margaret Kasner, MD, Thomas jefferson University;
Ubaldo Martinez, MD, Kimmel Cancer Center, Thomas Jefferson University;
Mark Weiss, MD, Kimmel Cancer Center, Thomas Jefferson University;
Neal Flomenberg, MD, Kimmel Cancer Center, Thomas Jefferson University
END Organ Disease in the Context of Human Herpes VIRUS 6 Viremia in Pediatric Allogeneic Hematopoietic STEM CELL Transplant Patients: A Case Series
Lena Winestone, MD, Stanford University;
Rajni Agarwal, MD, Stanford University;
Jose Montoya, MD, Stanford University;
Kenneth I Weinberg, MD, Pediatric Stem Cell Transplantation, Stanford University;
Matthew H. Porteus, MD, Stanford University;
Benjamin Pinsky, MD, Ph.D, Stanford University;
Elizabeth Soda, MD, Stanford University;
Jesse Waggoner, MD, Stanford University;
John Tamaresis, Ph.D, Pediatrics, Stanford University;
Sandhya Kharbanda, MD, Pediatric Stem Cell Transplantation, Stanford University
Impact of Adenovirus Viremia in Bone Marrow Transplant Patients, 2010-2013
Steven Wu, The Ohio State University College of Medicine;
Nicole Theodoropoulos, MD, The Ohio State University;
Stanley I Martin, MD, The Ohio State University;
Leslie A Andritsos, MD, The Ohio State University;
Steven M. Devine, MD, Ohio State Medical Center
